English >>
TOPページ
現在の専門分野
著書
学術雑誌
学会発表
所属学会
(最終更新日:2022-02-25 18:21:24)
キタナカ アキラ
北中 明
所属
川崎医科大学 医学部 臨床医学 検査診断学(病態解析)
職種
教授
■
現在の専門分野
キーワード:血液腫瘍学、臨床検査医学
■
著書
1.
2018/11
部分執筆
B 病態・臨床検査(1 一般検査(尿検査,糞便検査,脳脊髄液検査), 2 血液学的検査, 3 臨床化学検査, 4 免疫学的検査)「薬物治療総論/症候・臨床検査/個別化医療
臨床薬学テキストシリーズ」
2.
2018/10
部分執筆
I.造血器腫瘍の新しい分類 1.WHO分類改訂第4版(2017)における骨髄系腫瘍「EBM 血液疾患の治療 2019-2020」
3.
2018/01
部分執筆
骨髄異異形性症候群「今日の治療指針 2018年版」
4.
2021/05
部分執筆
第5章 結果の評価 C 赤血球系疾患 e.赤血球増加症「スタンダード検査血液学」
5.
2020/01
部分執筆
骨髄穿刺法、生検法 (適応と方法)「今日の治療指針 2020年版」
6.
2015/12
部分執筆
骨髄線維症 (MF)「難病辞典」
5件表示
全件表示(6件)
■
学術雑誌
1.
2019/08
原著
Binimetinib, a novel MEK1/2 inhibitor, exerts anti-leukemic effects under inactive status of PI3Kinase/Akt pathway.
2.
2019/03
原著
Mice with Calr mutations homologous to human CALR mutations only exhibit mild thrombocytosis.
3.
2018/07
症例報告
進行する貧血・好中球減少を呈した症例
4.
2018/03
原著
Lemongrass essential oil and citral inhibit Src/Stat3 activity and suppress the proliferation/survival of small-cell lung cancer cells, alone or in combination with chemotherapeutic agents.
5.
2018/02
総説
血液形態診断のためのケースカンファレンス 司会のまとめ(第64回学術集会シンポジウム10)
6.
2018/01
総説
骨髄異形成症候群の診断と病型分類update -2016年改訂WHO分類を踏まえて-
7.
2018/01
原著
Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma.
8.
2017/09
原著
A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study).
9.
2017/05
原著
Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib.
10.
2017/05
原著
Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice.
11.
2017/03
原著
TET2 mutation in diffuse large B-cell lymphoma.
12.
2017/03
原著
ルーチン検査(基本的検査)の読み方・考え方 信州大学方式RCPC
13.
2017/03
原著
Development of a complete human IgG monoclonal antibody to transferrin receptor 1 targeted for adult T-cell leukemia/lymphoma.
14.
2017/03
原著
Differences in Hematological and Clinical Features Between Essential Thrombocythemia Cases With JAK2- or CALR-Mutations.
15.
2016/10
総説
CML進行期の対応
16.
2016/09
総説
骨髄異形成/骨髄増殖性腫瘍(分類不能型)の臨床的特徴と治療の選択肢
17.
2016/09
症例報告
骨髄移植後にHHV-6脳炎、髄液内再発をきたしたATLLの一例
18.
2016/05
原著
Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.
19.
2016/05
原著
All-trans retinoic acid and interferon-alpha increase CD38 expression on adult T-cell leukemia cells and sensitize them to T cells bearing anti-CD38 chimeric antigen receptors.
20.
2016/05
総説
本態性血小板血症の治療 アナグレリドの位置付け
21.
2016/04
原著
Splenic irradiation provides transient palliation for symptomatic splenomegaly associated with primary myelofibrosis: a report on 14 patients.
22.
2016/09
総説
骨髄異形成/骨髄増殖性腫瘍(分類不能型)の臨床的特徴と治療の選択肢
23.
2016/02
原著
Variegated RHOA mutations in adult T-cell leukemia/lymphoma.
24.
2015/12
原著
Surrounding Gastric Mucosa Findings Facilitate Diagnosis of Gastric Neoplasm as Gastric Adenoma or Early Gastric Cancer.
25.
2015/12
原著
TET2 Mutation in Adult T-Cell Leukemia/Lymphoma.
26.
2015/11
症例報告
Nasopharyngeal carcinoma with bone marrow metastasis: positive response to weekly paclitaxel chemotherapy.
27.
2015/11
原著
Integrated molecular analysis of adult T cell leukemia/lymphoma.
28.
2015/09
原著
Analysis of the molecular mechanism underlying bone marrow necrosis with acute lymphoblastic leukemia.
29.
2015/04
原著
Gene expression profiling of loss of TET2 and/or JAK2V617F mutant hematopoietic stem cells from mouse models of myeloproliferative neoplasms.
30.
2015/01
原著
Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator.
31.
2014/12
原著
Cbl negatively regulates erythropoietin-induced growth and survival signaling through the proteasomal degradation of Src kinase.
32.
2014/04
原著
Clinical outcomes of AIDS-related Burkitt lymphoma: a multi-institution retrospective survey in Japan.
33.
2014/03
総説
本邦における原発性骨髄線維症の臨床像
34.
2013/10
総説
骨髄増殖性腫瘍の分子機構と新規薬物療法
35.
2013/06
症例報告
遺伝性球状赤血球症にみられた髄外造血巣
36.
2013/01
原著
Effect of L-thyroxine replacement on apolipoprotein B-48 in overt and subclinical hypothyroid patients.
37.
2012/10
原著
TET2 is essential for survival and hematopoietic stem cell homeostasis.
38.
2012/09
原著
Acute myeloid leukemia in clinical practice: a retrospective population-based cohort study in Miyazaki Prefecture, Japan.
39.
2012/08
原著
Linezolid-induced pure red cell aplasia in a patient with Staphylococcus epidermidis infection after allogeneic stem cell transplantation.
40.
2012/06
原著
T-cell immunotherapy with a chimeric receptor against CD38 is effective in eradicating chemotherapy-resistant B-cell lymphoma cells overexpressing survivin induced by BMI-1.
41.
2012/03
原著
The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo.
42.
2012/02
原著
T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells.
43.
2011/11
原著
S-1 induced secondary acute erythroid leukemia with a chromosome inv(12)(p13;q13).
44.
2011/10
総説
造血障害とその治療
45.
2011/10
原著
Medical cost analysis for antifungal prophylaxis in neutropenic patients with hematological malignancies: a systematic simulation analysis.
46.
2011/06
原著
Expression of CD38 with intracellular enzymatic activity: a possible explanation for the insulin release induced by intracellular cADPR.
47.
2011/02
症例報告
分娩後に発症した後天性血友病の1症例
48.
2010/12
原著
The immature platelet fraction is a useful marker for predicting the timing of platelet recovery in patients with cancer after chemotherapy and hematopoietic stem cell transplantation.
49.
2010/10
原著
Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
50.
2010/09
原著
Micafungin does not influence the concentration of tacrolimus in patients after allogeneic hematopoietic stem cell transplantation.
51.
2010/06
原著
Immature platelet fraction measurement in patients with chronic liver disease: a convenient marker for evaluating cirrhotic change.
52.
2010/03
原著
Automated assay for determining cellular cholesterol using a random access chemistry analyser.
53.
2010/02
総説
抗凝固物質測定の問題点と標準化に向けての取り組み 凝固阻害物質検出のための混合試験の実際と問題点
54.
2010/02
原著
Lineage switch from precursor B cell acute lymphoblastic leukemia to acute monocytic leukemia at relapse.
55.
2010/01
原著
Tec protein tyrosine kinase inhibits CD25 expression in human T-lymphocyte.
56.
2009/12
原著
Gab1 transduces PI3K-mediated erythropoietin signals to the Erk pathway and regulates erythropoietin-dependent proliferation and survival of erythroid cells.
57.
2009/12
原著
多項目自動血球分析装置XE-2100を用いた幼若血小板比率測定の臨床的有用性 化学療法および造血幹細胞移植後の血小板回復時期の予測マーカーとして
58.
2009/09
原著
Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma.
59.
2009/06
原著
Fludarabine and melphalan conditioning with tacrolimus as GVHD prophylaxis for allogeneic stem cell transplant recipients is an effective reduced-intensity combination regimen compared to the conventional regimen.
60.
2009/03
症例報告
Intravascular large B-cell lymphoma with FDG accumulation in the lung lacking CT/(67)gallium scintigraphy abnormality.
61.
2008/02
原著
Inhibition of Src reduces gemcitabine-induced cytotoxicity in human pancreatic cancer cell lines.
62.
2006/11
原著
Src transduces signaling via growth hormone (GH)-activated GH receptor (GHR) tyrosine-phosphorylating GHR and STAT5 in human leukemia cells.
63.
2005/04
原著
Cyclosporin A inhibits the early phase of NF-kappaB/RelA activation induced by CD28 costimulatory signaling to reduce the IL-2 expression in human peripheral T cells.
64.
2004/08
原著
Constitutive activation of PI3K is involved in the spontaneous proliferation of primary acute myeloid leukemia cells: direct evidence of PI3K activation.
65.
2004/06
原著
Constitutively activated phosphatidylinositol 3-kinase primes platelets from patients with chronic myelogenous leukemia for thrombopoietin-induced aggregation.
66.
2004/05
原著
Identification of p46 Shc expressed in the nuclei of hepatocytes with high proliferating activity: Study of regenerating rat liver.
67.
2004/03
原著
Analysis of the optimal blood sampling conditions for estimation of hematopoietic progenitor cell count by the SE-9000 automated hematolyzer.
68.
2001/10
原著
Src transduces erythropoietin-induced differentiation signals through phosphatidylinositol 3-kinase.
69.
2001/10
原著
Src directly tyrosine-phosphorylates STAT5 on its activation site and is involved in erythropoietin-induced signaling pathway. Oncogene
70.
2001/09
原著
Growth hormone prevents Fas-induced apoptosis in lymphocytes through modulation of Bcl-2 and caspase-3.
71.
2000/08
原著
Mediation by the protein-tyrosine kinase Tec of signaling between the B cell antigen receptor and Dok-1.
72.
2000/02
総説
CD38 in hematopoiesis.
73.
2000/01
原著
CD38 ligation inhibits normal and leukemic myelopoiesis.
74.
1999/10
原著
Molecular cloning of a docking protein, BRDG1, that acts downstream of the Tec tyrosine kinase.
75.
1999/02
原著
CD38-mediated signaling events in murine pro-B cells expressing human CD38 with or without its cytoplasmic domain.
76.
1998/02
原著
Expression and activation of the nonreceptor tyrosine kinase Tec in human B cells.
77.
1997/07
原著
CD38 ligation in human B cell progenitors triggers tyrosine phosphorylation of CD19 and association of CD19 with lyn and phosphatidylinositol 3-kinase.
78.
1997/04
原著
Antisense src expression inhibits tyrosine phosphorylation of Shc and its association with Grb2 and Sos which leads to MAP kinase activation in U937 human leukemia cells.
79.
1996/12
総説
Human B-cell progenitors and bone marrow microenvironment.
80.
1996/07
原著
CD38-mediated growth suppression of B-cell progenitors requires activation of phosphatidylinositol 3-kinase and involves its association with the protein product of the c-cbl proto-
81.
1996/02
原著
Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia.
82.
1996/01
原著
CD38 signal transduction in human B cell precursors. Rapid induction of tyrosine phosphorylation, activation of syk tyrosine kinase, and phosphorylation of phospholipase C-gamma and phosphatidylinositol 3-kinase.
83.
1994/11
原著
Low-dose continuous subcutaneous infusion of granulocyte colony-stimulating factor for chemotherapy-induced neutropenia in acute myelogenous leukemia and its pharmacokinetics.
84.
1994/06
原著
Antisense src expression inhibits U937 human leukemia cell proliferation in conjunction with reduction of c-myb expression.
85.
1994/06
原著
Antisense src expression inhibits proliferation and erythropoietin-induced erythroid differentiation of K562 human leukemia cells.
86.
2022/02
症例報告
Immunohistopathological Analysis of Extramedullary Hematopoiesis and Angiogenesis of Spleen in a Case of Primary Myelofibrosis with Huge Splenomegaly
87.
2021/10
原著
Whole-genome landscape of adult T-cell leukemia/lymphoma.
88.
2021/09
原著
Single-Cell Analysis of the Multicellular Ecosystem in Viral Carcinogenesis by HTLV-1.
89.
2021/05
原著
VLX1570 induces apoptosis through the generation of ROS and induction of ER stress on leukemia cell lines
90.
2021/03
原著
Association between microRNA-527 and glypican-3 in hepatocellular carcinoma
91.
2020/12
原著
Higher average chemotherapy dose intensity improves prognosis in patients with aggressive adult T-cell leukemia/lymphoma
92.
2020/08
総説
骨髄系腫瘍の臨床 慢性骨髄性白血病 移行期・急性転化期の慢性骨髄性白血病の病因・病態と治療
93.
2020/07
症例報告
血液形態診断のためのケースカンファレンス 細胞形態の特徴から診断し得た病初期の急性前骨髄球性白血病の1症例
94.
2020/06
原著
パニック値を巡る諸問題と日本臨床検査医学会からの提言 検体系検査のパニック値を巡る諸問題
95.
2020/02
原著
Clinical significance of soluble CADM1 as a novel marker for adult T-cell leukemia/lymphoma.
96.
2020/02
総説
造血器腫瘍のWHO分類改訂第4版(2017年)のポイント 骨髄系腫瘍
97.
2019/07
症例報告
血液形態診断のためのケースカンファレンス 骨髄標本に赤芽球の増加を認めた汎血球減少症の一例
98.
2018/06
原著
An MDS-derived cell line and a series of its sublines serve as an in vitro model for the leukemic evolution of MDS
5件表示
全件表示(98件)
■
学会発表
1.
2018/11/17
シンポジウム8 血液形態診断のためのケースカンファレンス
「骨髄標本に赤芽球の増加を認めた汎血球減少症の一例」 (口頭発表,シンポジウム・ワークショップ・パネルディスカッション等)
2.
2017/11/18
シンポジウム10 血液形態診断のためのケースカンファレンス
「進行する貧血・好中球減少を呈した症例」 (口頭発表,シンポジウム・ワークショップ・パネルディスカッション等)
3.
2017/09/30
アルブミン適正使用の推進:アルブミン製剤一元管理の効果と腹水ろ過濃縮再静注法(CART)の取り組み (口頭発表,一般)
4.
2016/09/04
RCPC2 ルーチン検査(基本的検査)の読み方・考え方―信州大学方式 RCPC― (口頭発表,シンポジウム・ワークショップ・パネルディスカッション等)
5.
2016/10/13
教育講演18 CML進行期の対応 (口頭発表,シンポジウム・ワークショップ・パネルディスカッション等)
6.
2019/11/24
パニック値を巡る諸問題と日本臨床検査医学会からの提言
1. 検体系検査のパニック値を巡る諸問題 (口頭発表,シンポジウム・ワークショップ・パネルディスカッション等)
7.
2019/11/24
教育講演 4 造血器腫瘍の WHO-2017 分類のポイント
造血器腫瘍の WHO 分類改訂第 4 版(2017)のポイント 骨髄系腫瘍 (口頭発表,シンポジウム・ワークショップ・パネルディスカッション等)
5件表示
全件表示(7件)
■
所属学会
1.
1991~
日本血液学会
2.
2014~
∟ 評議員
3.
1991~
日本内科学会
4.
2016~
∟ 中国支部評議員
5.
2001~
日本輸血細胞治療学会
6.
2017~
∟ 輸血機能評価認定制度視察員 (I&A制度視察員)
7.
2002~
日本臨床検査医学会
8.
2018~
∟ 医療安全委員
9.
2002~
米国血液学会
10.
2007~
日本臨床検査専門医会
11.
2022~
∟ 理事
12.
2016~
日本検査血液学会
5件表示
全件表示(12件)